1M6MYTD1Y5YMAX
Loading quotes...
Forecast
There is no analyst data available for this company.
News Go to news feed
There is currently no news available for this company. We are working on adding more providers to change this.
Financials
| (EUR) | 2024 | |
|---|---|---|
| Revenue | 7,00 Mio | 145,79% |
| Gross profit | −23,56 Mio | 23,93% |
| Net profit | −51,40 Mio | 4,58% |
| EBITDA | −49,80 Mio | 1,29% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | 6,36 Mio€ |
Number of shares | 64,25 Mio |
52-week high/low | 1,51€ - 0,085€ |
| Dividends | No |
Beta | 1,02 |
P/E ratio | −0,04 |
PEG ratio | 0,00 |
P/B ratio | −0,04 |
P/S ratio | 0,91 |
Company profile
Carmat SA entwirft und entwickelt vollständige Kunstherzen für Menschen mit biventrikulärer Herzinsuffizienz im Endstadium in Frankreich und international. Das Unternehmen wurde 2008 gegründet und hat seinen Hauptsitz in Vélizy-Villacoublay, Frankreich.
| Name | Carmat |
| CEO | Stephane Piat |
| Headquarters | Vélizy-Villacoublay,
France |
| Website | |
| IPO | 07/13/2010 |
| Employees | 162 |
Ticker symbols
| Exchange | Symbol |
|---|---|
Euronext | ALCAR.PA |
Pnk | CKMTF |
Frankfurt | CXT.F |
Düsseldorf | CXT.DU |
Paris | ALCAR.PA |
München | CXT.MU |
Discover assets
Shareholders of Carmat also invest in the following assets
